Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 37 of 37 publications.

Morris MJ, de Bono J, Nagarajah J, Sartor O, Wei XX, Nordquist LT, Koshkin VS, Chi KN, Krause BJ, Herrmann K, Rahbar K, Vickers A, Mirante O, Ghouse R, Fizazi K, Tagawa ST. Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: analysis of the phase 3 VISION trial. Cancer. 2024 Oct 15;130(20):3426-35. doi: 10.1002/cncr.35438

Vickers A, Leng X. The impact of life expectancy exclusion criteria on survival curve extrapolation. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S406. doi: 10.1016/j.jval.2023.09.2131

Vickers A. The performance of anchored and unanchored population adjustment methods (matching-adjusted indirect comparison, simulated treatment comparison, and multiple imputation marginalization) in castration resistant prostate cancer. Poster presented at the ISPOR Europe 2023; November 12, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S400-1. doi: 10.1016/j.jval.2023.09.2098

Jen MH, Kiiskinen U, Khanal M, Han Y, Hess L, Tian W, Vickers A. Matching Adjusted Indirect Comparison (MAIC) of selpercatinib Vs cabozantinib in RET mutation-positive advanced Medullary Thyroid Cancer (MTC). Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S18. doi: 10.1016/j.jval.2023.09.094

Morris MJ, Armstrong AJ, Chi K, de Bono J, Herrmann K, Krause B, Rahbar K, Sartor O, Tagawa ST, Nagarajah J, Wei XX, Nordquist LT, Koshkin VS, Saad F, Vickers A, Ghouse R, Wu J, Mirante O, Fizazi K. Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer. Poster presented at the ESMO Congress 2023; October 22, 2023. Madrid, Spain.

Vickers A. A comparison of the performance of a range of trial-level surrogacy methods. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S357. doi: 10.1016/j.jval.2022.09.1771

Wolowacz S, Bhatnagar V, Vickers A, Pickaert AP. Clinical evidence for health technology assessment in oncology, are we going backwards? Where are we going with single-arm trials? Presented at the ISPOR Europe 2022; November 8, 2022. Vienna, Austria.

Morris MJ, de Bono J, Nagarajah J, Wei XX, Nordquist T, Koshkin VS, Vickers A, Mirante O, Ghouse R, Tagawa S, Fizazi K. Radiographic progression‑free survival correlation with time‑to‑event endpoints: a post hoc analysis of the VISION trial. Poster presented at the 2022 ESMO Annual Congress; September 9, 2022. Paris, France. [abstract] Ann Oncol. 33(supplement 3):S1170-1. doi: 10.1016/j.annonc.2022.07.1506

Rolfo C, Hess LM, Jen MH, Peterson P, Li X, Liu H, Lai Y, Sugihara T, Kiiskinen U, Vickers A, Summers Y. External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer. ESMO Open. 2022 Aug;7(4):100551. doi: 10.1016/j.esmoop.2022.100551

Jen MH, Sonksen M, Kiiskinen U, Wolowacz S, Vickers AD, Hawe E. Surrogate outcomes for overall survival in pretreated non-small cell lung cancer: expanding the prediction range. Poster presented at the Virtual ISPOR Europe 2021; December 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

DeBusk K, Abeysinghe S, Vickers A, Nangia A, Bell J, Ike C, Forero-Torres A, Blahna MT. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. Future Oncol. 2021 Nov;17(33):4635-47. doi: 10.2217/fon-2021-0742

Vickers A, Nag A, Devine B, Sands BE, Panaccione R, Peyrin-Biroulet L, Danese S, Vermeire S, Gorelick KJ, Goetsch M, Hartley L. Induction of response and remission: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis. Poster presented at the 2020 15th Congress of the European Crohn’s and Colitis Organisation (ECCO); February 2020. Vienna, Austria.

Vickers A, Nag A, Devine B, Sands BE, Panaccione R, Peyrin-Biroulet L, Danese S, Vermeire S, Gorelick KJ, Goetsch M, Hartley L. Induction of endoscopic response: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis. Poster presented at the 2020 European Crohn's and Colitis Organisation Annual Congress; February 2020. Vienna, Austria.

Vickers A. An evaluation of survival curve extrapolation techniques using long-term observational cancer data. Med Decis Making. 2019 Nov;39(8):926-38. doi: 10.1177/0272989X19875950

Zuluaga-Sanchez S, Teynor M, Knight C, Thompson R, Lundqvist T, Ekelund M, Forsmark A, Vickers AD, Lloyd A. Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden. Pharmacoeconomics. 2019 Jun;37(6):845-65. doi: 10.1007/s40273-019-00769-6

Vickers AD, Winfree KB, Cuyun Carter G, Kiiskinen U, Jen MH, Stull D, Kaye JA, Carbone DP. Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis. BMC Cancer. 2019 Apr 15;19(1):353. doi: 10.1186/s12885-019-5569-5.

Vickers AD, Hawe E. An evaluation of survival curve extrapolation techniques using long-term observational cancer data. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain.

Zuluaga-Sanchez S, Hess LM, Wolowacz SE, D'yachkova Y, Hawe E, Vickers AD, Kaye JA, Bertwistle D. Cost-effectiveness of olaratumab in combination with doxorubicin for patients with soft tissue sarcoma in the United States. Sarcoma. 2018 Mar 26;2018:6703963. doi: 10.1155/2018/6703963

Ainsworth CM, Vickers AD, Le Moine J. Assessing the robustness of network meta-analysis of atypical antipsychotics in the presence of heterogeneity. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 8, 2017. Glasgow, Scotland. [abstract] Value Health. 2017 Oct; 20(9):A767. doi: 10.1016/j.jval.2017.08.2189

Zuluaga S, Hess LM, Wolowacz S, Dyachkova Y, Hawe E, Vickers AD, Kaye JA, Bertwistle D. Cost-effectiveness of olaratumab in combination with doxorubicin for the treatment of locally advanced or metastatic soft tissue sarcoma in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A108.

Bertwistle D, D'yachkova Y, Vickers AD, Hawe E, Fernandez M, Drove N, Lorenzo M, Wolowacz S. Comparative efficacy and saftey of interventions in the treatment of advanced soft tissue sarcoma: a systematic review and network meta analysis. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A712.

Vickers AD, Ainsworth C, Mody R, Bergman A, Ling CS, Medjedovic J, Smyth M. Systematic review with network meta-analysis: comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis. PLoS One. 2016 Oct 24;11(10):e0165435. doi: 10.1371/journal.pone.0165435

Vickers AD. Survival network meta-analysis: hazard ratios versus reconstructed survival data. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A90.

Hawe E, Vickers A, Mollon P, Mcbride D, Stull D. Secukinumab 300mg demonstrates highest probability of efficacy than other biologics in psoriasis: indirect comparison. Poster presented at the 24th European Academy of Dermatology and Venereology (EADV) Congress; October 2015. Copenhagen, Denmark. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.

Collins A, Hawe E, Vickers A, Mallya UG, Mcbride D, Capkun-Niggli G, Olson M, Thorlund K. Secukinumab 300 mg demonstrates higher probability of efficacy than other biologics in psoriasis: indirect comparison. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia.

Vickers AD, Mody R, Bergman A, Ling CS, Ainsworth C, Medjedovic J, Smyth M. Comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis (UC): a systematic review and network meta-analysis. Poster presented at the 2015 Digestive Disease Week; May 2015. Washington, DC. [abstract] Gastroenterology. 2015 Apr 16; 148(4, Suppl 1):S272. Previously presented at the 10th Congress of the European Crohn's and Colitis Organization.

Vickers AD, Mody RR, Bergman A, Ling CS, Ainsworth C, Medjedovic J, Smyth M. Comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis (UC): a systematic review and network meta-analysis. Poster presented at the 10th Congress of the European Crohn's and Colitis Organization; February 18, 2015. Barcelona, Spain. [abstract] J Crohns Colitis. 2015 Feb 2; 9(Suppl 1):S357-8. doi: 10.1093/ecco-jcc/jju027.672

Hawe E, Vickers AD, Mallya UG, McBride DW, Capkun-Niggli G, Olson M, Thorlund K. Secukinumab 300mg demonstrates highest probability of efficacy than other biologics in psoriasis: indirect comparison. Poster presented at the 23rd European Academy of Dermatology and Venereology Congress; October 2014. Amsterdam, the Netherlands.

Small M, Vickers AD, Anderson P, Kay S. The patient-physician partnership in asthma: real-world observations associated with clinical and patient-reported outcomes. Adv Ther. 2010 Sep;27(9):591-9. doi: 10.1007/s12325-010-0054-1

Vickers AD, Mellor P. Identifying click-throughs in choice-based conjoint studies. Presented at the Advanced Research Techniques Forum of the American Marketing Association; 2009.

Vickers AD, Sochaczewski L, Mellor P, Brice R. Random forests – Application and comparisons with other data mining and statistical techniques using the example of treatment decision making in health care. Poster presented at the Advanced Research Techniques Forum of the American Marketing Association; 2007.

Vickers AD, Mellor P, Brice R. Over-estimation in market simulations: an explanation and solution to the problem with particular reference to the pharmaceutical industry. Presented at the Eleventh Sawtooth Software Conference; October 6, 2004. San Diego, CA.

Vickers AD. Adapting market simulations from choice-based conjoint analysis to pharmaceutical scenarios. Presented at the Annual Sawtooth Software Conference; 2004.

Hill AR, Aspinall P, Armbrecht A, Lumsden C, Nelson P, Brice R, Vickers AD. Utilities for quality of life from time trade-off and conjoint analysis in age-related macular degeneration. Poster presented at the Heriott Watt University; 2004.

Vickers AD, Rotherham ID, Rose J. Vegetation succession and colonisation rates at the forest edge under different environmental conditions. Ann Appl Biol. 2000;58:1-8.

Vickers AD, Rotherham ID. The response of Bluebell (Hyacinthoides non-scripta) to seasonal differences between years and woodland management. Ann Appl Biol. 2000;58:351-6.

Vickers AD, Palmer SCF. The influence of canopy cover and other factors upon regeneration of Scots pine and associated ground flora within Glen Tanar NNR. Forestry (Lond). 2000;73(1):37-49.